AstraZeneca's ASCO 'super sunday' delivers new data for Tagrisso and Imfinzi in lung cancer and Enhertu in breast cancer
called BNT-327, had positive results in patients with triple negative breast cancer. If future trials on the bispecific produce more positive data, it could become a critical part of how triple negative
Triple-negative breast cancer (TNBC) is a particularly aggressive breast cancer subtype, characterised by a higher incidence in younger women, rapid metastasis, and a generally poor prognosis. Patients with TNBC and BRCA mutations face additional therapeutic challenges due to the cancer’s intrinsic re...
Triple-negative breast cancer (TNBC) is a particularly aggressive breast cancer subtype, characterised by a higher incidence in younger women, rapid metastasis, and a generally poor prognosis. Patients with TNBC and BRCA mutations face additional therapeutic challenges due to the cancer’s intrinsic re...
In about 20% of breast cancers, the cells make too much of a protein known as HER2. These cancers tend to be aggressive and fast-growing. For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the risk of the cancer coming...
positive for hormone receptors means good response to treatment,” Dr Fazilli said, “Ovarian cancer and breast cancer, both depend on hormones (estrogen hormone – the female hormone) TNEOC; A subtype of ovarian cancer that lacks expression of estrogen receptor, progesterone receptor, and human ...
A Benefit to Add-On Abemaciclib in Advanced Breast Cancer? news New Approaches in the Treatment of HR+ Metastatic Breast Cancer news Evolving Landscape of HR-Positive Metastatic Breast Cancer: A Year in Review 1.25 CME / ABIM MOC Credits Comments...
Tecentriq may be used alone as the first treatment in patients with lung cancer if: Their cancer has spread or grown,and Their cancer tests positive for “high PD-L1”and Their tumor does not have an abnormal “EGFR” or “ALK” gene. ...
Study leader Luca Gianni from the San Raffaele Cancer Center in Milan, Italy explains: Approximately one in five breast cancer tumors is HER-2 positive. The standard treatment for HER-2 positive women is trastuzumab, a monoclonal antibody that is designed to inhibit the cancer-causing activity ...
The list includes the E2F transcription factor network, which we reported to be K19-dependent using hormone-positive breast cancer cells [21]. Identification of genes involved in promoting cancer and cell migration is a strong indication that transcriptomic changes of those genes significantly ...